NICE sticks with no for Cell Therapeutics' Pixuvri
This article was originally published in Scrip
Executive Summary
Cell Therapeutics has two weeks to appeal against negative recommendations from NICE, the health technology appraisal body for England and Wales, on the firm's anticancer Pixuvri (pixantrone). NICE still does not believe the drug would be a cost-effective use of NHS resources.